Latest Market Entry News

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.

Stakk Limited reports a staggering 2,533% quarter-on-quarter increase in annual recurring revenue to $472k, fueled by its acquisition of US-based Radical DBX and rapid expansion in Embedded Finance across Australia and the US.

HITIQ Limited is pivoting towards grassroots athletes with its upcoming PROTEQT concussion management system, backed by strategic partnerships and fresh funding. The company aims for a cashflow positive future as it prepares for commercial rollout.

Audio Pixels Holdings Limited reports significant progress in its MEMS fabrication and ASIC development, targeting wafer completion by Q2 2025 while managing funding and ASX suspension challenges.

1414 Degrees Ltd advances its transformation into a full-service decarbonised energy provider, delivering key technology and commercial milestones in Q3 FY25 while maintaining a stable cash position.

Green Critical Minerals has fast-tracked its VHD Graphite pilot plant commissioning, producing prototype blocks with record-breaking density and thermal performance, while securing strategic partnerships and advancing key projects.

Strategic Elements Ltd (ASX: SOR) reported meaningful progress in its Energy Ink™ technology and underground mining platform during Q1 2025, while maintaining a robust cash balance and preparing for international collaborations.

Pointerra Limited’s Q3 FY25 results reveal delayed invoicing milestones pushed into Q4, yet strong progress across multiple sectors and promising product development underpin an optimistic cashflow outlook.

RLF AgTech has secured major national distribution agreements in Australia, launched a comprehensive retail rollout, and restructured its manufacturing arm, LiquaForce, to drive growth and operational efficiency. The company also reported strong financial performance and expanded its footprint across Asia.

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.